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Measurement of serum alpha-fetoprotein (AFP, reference range
< 10 ng ml–1) provides a marker for the diagnosis and management
of hepatocellular carcinoma (HCC) (Johnson et al, 1978; Nomura
et al, 1985; Sheu et al, 1985) and non-seminomatous germ cell
tumours (NSGCT) (Lange and Fralay, 1977; Javadpour 1980; Kay
et al, 1987; Nichols et al, 1990). About 70% of patients with HCC
will have levels above the reference range (Johnson et al, 1978;
Nomura et al, 1985; Sheu et al, 1985). A serum concentration of
greater than 500 ng ml–1, in an HCC high-incidence area, and in
the appropriate clinical setting, is usually diagnostic of HCC.
However, modestly raised levels of AFP (10–500 ng ml–1) are also
common in non-malignant chronic liver disease, so that the speci-
ficity of the AFP test for HCC tends to be low (Johnson et al,
1978; Okuda, 1986; Lok and Lai, 1989). This represents a serious
clinical drawback for the test since most cases of HCC arise in
patients with concurrent chronic liver disease (Kew and Popper,
1984; Johnson and Williams, 1987).
AFP is a glycoprotein consisting of 591 amino acids that has
been reported to have a single asparagine linked complex-type
sugar chain (Tarelli et al, 1992; Ferranti et al, 1995). Although it
has been known for over 20 years that serum AFP exhibits micro-
heterogeneity when examined by isoelectric focusing (IEF), the
biomolecular basis for this heterogeneity has remained controver-
sial (Ruoslahti 1979; Smith and Kelleher, 1980). Recently, we
have used fluorescence labeling, sequential exoglycosidase diges-
tion, high-performance liquid chromatography and matrix-assisted
laser desorption ionization in time-of-flight mass spectrometry, to
determine the glycan structures of purified serum AFP from
patients with HCC and NSGCT. Surprisingly, eleven major
glycans were found, of which seven were N-linked, and four were
O-linked, to the protein backbone (Figure 1) (Johnson et al, 1999).
Several attempts have been made to identify an ‘HCC-specific’
glycoform, aiming thereby to improve the specificity of AFP as a
diagnostic test for HCC. The most successful approach has been
based on the difference in the binding affinity of the AFP glyco-
forms to various lectins, particularly lentil lectin and Concanavalin
A. Indeed, different binding patterns were found in AFP from
patients with different diseases (Smith and Kelleher, 1980;
Buamah et al, 1986; Du et al, 1991). More recently, using IEF to
directly identify isoforms of AFP, the Band + II and Band + III
AFP isoforms were shown to be highly specific for HCC (Burditt
et al, 1994; Ho et al, 1996) and NSGCT (Johnson et al, 1995),
respectively. A unique IEF pattern is also found for the AFP that
arises in patients with chronic liver disease without any evidence
of malignancy (Ho et al, 1996; Johnson et al, 1997). Preliminary
studies have suggested that screening for the Band + II isoform
may allow early, even preclinical, diagnosis of HCC in high-risk
patients (Johnson et al, 1997). However, the current protocol of
IEF and immunoblotting techniques for identification of the
tumour-specific isoform is very time-consuming and it is therefore
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Summary Alpha-fetoprotein (AFP) is widely used as a serological marker in the diagnosis of hepatocellular carcinoma (HCC) and
non-seminomatous germ cell tumours (NSGCT). By application of isoelectric focusing (IEF) disease-specific AFP isoforms can be identified.
Three major bands are apparent: + l (associated with ‘benign’ liver disease), + II (associated with HCC) and +III (associated with NSGCT).
Recently, we have characterized the predominant glycans of human serum AFP and now report the application of these findings and
electrospray ionization-mass spectrometry (ESI-MS) to the determination of the glycan composition of the isoforms present in the sera of
12 patients with HCC and of one patient with NSGCT. ESI-MS allowed simultaneous identification of various AFP glycoforms in purified serum
AFP. Seven glycoforms were identified, but with different abundance in the sera of the HCC patients, whereas six glycoforms were identified
in the serum from the NSGCT patient. The glycan structures of these glycoforms were deduced from their observed masses. AFP glycoforms
carrying a single biantennary complex-type N-glycan appeared as the predominant glycoforms, whereas those carrying both N-glycan and
O-glycan appeared as minor glycoforms. Correlation between the abundance of the AFP glycoforms and the IEF band intensity suggested
that different degrees in sialylation cause the formation of isoforms. This contention was subsequently supported by the ESI-MS and kinetic
in vitro desialylation studies on purified Bands 1 l and 1 lI AFPs. Our findings indicate that HCC-associated isoforms (Band + II) represent a
group of glycoproteins whose carbohydrate structures are all characterized by being mono-sialylated, whereas those associated with benign
liver disease and NSGCT are di- and a-sialo species, respectively. Knowledge of the structure of the tumour-specific isoforms should form an
important basis for clinically useful assays. © 2000 Cancer Research Campaign
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this, it is essential to determine the biomolecular basis of the
disease-specific isoforms so as to identify any distinctive structural
features.
Although the carbohydrate structures of serum disease-specific
glycoforms have been proposed using the lectin affinity electro-
phoretic technique (Shimizu et al, 1996), the structures of the HCC
and NSGCT isoforms identified by IEF remain unknown. In this
study, using electrospray ionization-mass spectrometry (ESI-MS)
and applying our recent characterization of the 11 glycans of AFP,
we have elucidated the structures of the glycan moieties of those
AFP isoforms associated with disease-specific states, and related
these to the IEF banding patterns. ESI-MS and kinetic in vitro
desialylation studies were then applied to confirm the structures of
disease-specific isoforms.
MATERIALS AND METHODS
Patient sera
Sera were collected from 12 patients with histologically confirmed
HCC, all of whom had serum AFP levels of > 300 000 ng ml–1 (range
300 000–300 000 ng ml–1), and one patient with histologically
confirmed NSGCT with a serum AFP level of 17 820 ng ml–1.
The concentration of serum AFP was assayed by a microparticle
enzyme immunoassay (MEIA, Abbott Laboratories, Illinois,
USA). Sera were stored at –70°C until further analysis, or until
purification of the AFP.
Purification of AFP by one-step affinity
chromatography
Rabbit anti-human AFP (DAKO, Glostrup, Denmark) was
coupled to CNBr-activated Sepharose 4B (Pharmacia Biotech,
Uppsala, Sweden). A mini-column containing 1 ml of coupled gel
was equilibrated with phosphate buffered saline (PBS, 10 mM
sodium phosphate, 10 mM KCl, 127 mM NaCl, pH 7.4). The
sample to be purified (200–500 mg) was loaded into the column
and incubated at room temperature for 4 h. The column was then
washed with 50 ml of PBS containing 0.2% Tween 20, and subse-
quently with 50 ml of PBS. Bound AFP was eluted with 20 ml of
0.2 M Na2CO3 under gravity. The ‘total’ AFP concentration was
determined as previously described. The purity of the final AFP
preparation was regarded as acceptable when a single band, with
a molecular weight of about 68 kDa, was visualized on an SDS
PAGE gel using silver staining.
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Figure 1 The structures of the glycans on AFP associated with HCC and NSGCTPurification of AFP isoforms by preparative IEF and
affinity chromatography
Serum containing about 5 mg of AFP was applied to a mix-
ture of 5% sorbitol, 10% glycerol and ampholytes (6.25%
Pharmalyte pH 4.5–5.4, Pharmacia Biotech) which had been
pre-focused at constant power (15 W) for 30 min in a Rotofor
cell (Biorad, California, USA) at 4°C. The sample was then
focused at constant power (15 W) until the voltage stabilized
and then focused for a further 30 min before 20 individual 2 ml
fractions were harvested. pH and AFP concentration in each
fraction were measured. Fractions with more than 10 mg of AFP
were pooled and refractionated to improve the separation of the
isoforms. The pH and AFP concentration were again measured.
Fractions containing only Band +I or Band +II AFP, free of
other isoforms, were identified by gel IEF. Finally, the separated
AFP isoforms in the pooled fractions were purified by affinity
chromatography.
Isoelectric focusing-immunoblotting (IEF-IB)
The method of Burditt et al (1994) with minor modifications
was used. Samples were focused in 1.5 mm thick agarose gel
containing 1% agarose (IEF grade Type VIII, Sigma, Missouri,
USA) 5% sorbitol, 10% glycerol and ampholytes (6.25%
Pharmalyte pH 4.5–5.4, Pharmacia Biotech) at 10°C. After pre-
focusing at 1500 V for 30 min, samples were then applied directly
to the gel and focused at 2000 V for 1 h. The focused proteins
were transferred to nitrocellulose membrane, and then incubated
with horseradish peroxidase conjugated polyclonal rabbit anti-
human AFP (DAKO). After washing, the enhanced chemilumines-
cence detection system (ECL, Pharmacia Biotech) was used to
visualize the AFP protein bands.
ESI-MS analysis of purified AFPs
ESI-MS was performed on a triple quadrupole Quattro II system
(Micromass, Manchester, UK). The mass scale was calibrated with
a mixture of myoglobin and trypsinogen. The capillary voltage of
the electrospray probe was set to + 3.5 KV. The nebulizer gas was
set at 20 l h–1 and the drying gas at 250 l h–1. The source tempera-
ture was set at 75°C. The desalted AFP sample (5 pmol ml–1 in
50% acetonitrile in water containing 0.2% formic acid) was
injected into the ion source at a flow rate of 5 ml min–1. Positive
ionization mass spectra were acquired over the mass/charge ratio
(M/Z) range of 1000–2400 at 4 s per scan. The sampling cone
voltage was varied through the range of 47–90 V. The background
subtracted raw data was processed by the Maximum Entropy
(MaxEnt) software to produce the transformed mass spectrum.
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Figure 2 Typical IEF patterns of serum AFPs from patients with liver
cirrhosis only (LC), HCC (H) and NSGCT (G), and purified total AFP (T),
Band +I AFP (+I) and Band +II AFP (+II)
Table 1 The predominant AFP glycoforms in HCC identified by ESI-MS, and their deduced glycan compositions. Purified total AFPs from the sera of HCC
patients were subjected to ESI-MS analysis. All samples were measured for at least four times. The observed masses of the identified AFP glycoforms were
matched with the calculated masses of the hypothetical AFP glycoforms. Those observed AFP glycoforms in which mass difference was less than 0.01% were
considered to have the same molecular structure as the matched hypothetical AFP glycoforms
Observed mass Deduced glycan Calculated Monosaccharide Label
composition mass composition per
protein molecule
69048.5 ± 3.6 G11 + G1 + G5 69044.3 2 SA, 4 Hex, +Ia
6 HexNAc,
1 DeoxyHex
68797.4 ± 3.4 G7a 68800.0 2 SA, 5 Hex, +Ib
G11 + G2b + G2b 4 HexNAc,
1 DeoxyHex
68651.2 ± 3.8 G3 68653.9 2 SA, 5 Hex, +Ic
4 HexNAc
68754.4 ± 9.7 G11 + G2 + G5 68753.1 1 SA, 4 Hex, +IIa
6 HexNAc,
1 DeoxyHex
68708.0 ± 8.5 G8 + G5a 68712.0 1 SA, 5 Hex, +IIb
G10 + G2 68712.0 5 HexNAc,
G10 + G2b + G5 68712.0 1 DeoxyHex
G11 + G2b + G4 68712.0
68505.8 ± 3.1 G8 68508.8 1 SA, 5 Hex, +IIc
4 HexNAc,
1 DeoxyHex
68358.7 ± 4.6 G6 68362.7 1 SA, 5 Hex, +IId
4 HexNAc
aMost probable glycan composition within the groupThe accuracy of this method is ± 0.01%. All samples were
measured for 3–5 times.
Deduction of the glycan composition in AFP
glycoforms identified by ESI-MS
With the knowledge of the structures of eleven predominant
glycans on AFP glycoforms, the molecular masses for a series of
hypothetical AFP glycoforms comprising random combinations of
the N-linked and/or O-linked glycans were calculated. Their theo-
retical masses (average masses) were derived from the theoretical
mass of the AFP protein core (calculated with the Peptide Mass
software from ExPASy, accessed through the Internet at
http://expasy.hcuge.ch), and the theoretical masses of the mono-
saccharide residues reported by Dell et al (1993). The observed
masses of the AFP glycoforms identified by ESI-MS were then
matched with the calculated masses of the hypothetical AFP
glycoforms. Those observed AFP glycoforms in which mass
difference was less than 0.01% were considered to have the same
molecular structure as the matched hypothetical AFP glycoforms.
Kinetic in vitro desialylation of purified Band + I AFP
20 ml of 250 mU ml–1 sialidase (Vibrio cholerae neuraminidase,
Roche Diagnostics, Indianapolis, USA) was mixed with 10 ml of
purified Band + I AFP (800 mg ml–1) in reaction buffer (0.1 M Na
acetate, 9 mg ml–1 NaCl, 1 mg ml–1 CaCl2, pH 5.6), and incubated
at 37°C. At the assigned time for the individual assay tubes, the
reaction was stopped by adding 20 ml of stopping buffer (0.15 M
glycine-NaOH, pH 11.0). The final reaction mixture was subjected
to IEF-IB for the visualization of the AFP IEF banding patterns.
RESULTS
Identification of glycan composition of AFP glycoforms
in patient sera by ESI-MS
Total AFP was successfully purified from individual patient sera
(Figure 2), and subjected to ESI-MS analysis. Four major and
three minor AFP glycoforms, purified from the sera of the HCC
patients, were identified (Table 1). Three major and three minor
Structures of alpha-fetoprotein isoforms 1333
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Table 2 The predominant AFP glycoforms in NSGCT identified by ESI-MS, and their deduced glycan compositions. Purified total AFP from the serum of a
NSGCT patient (as per Table 1)
Observed mass Deduced glycan Calculated Monosaccharide Label
composition mass composition per
protein molecule
68803 ± 1.5 G7 68800.5 2 SA, 5 Hex, +Ib
G11 + G2b + G2b 4 HexNAc,
1 DeoxyHex
68712 ± 0.8a G10 + G2 68712.0 1 SA, 5 Hex,
G10 + G2b + G5 68712.0 5 HexNAc, +IIb
G11 + G2b + G4 68712.0 1 DeoxyHex
G8 + G5 68712.0
68511 ± 1.6 G8 68508.8 1 SA, 5 Hex, +IIc
4 HexNAc,
1 DeoxyHex
68342 + 2.3 G11 + G2b 68346.7 1 SA, 4 Hex, +IIe
4 HexNAc,
1 DeoxyHex
68423 ± 0.6c G10 + G4d 68420.7 5 Hex, 5 HexNAc, +IIIa
G9 + G5 68420.7 1 DeoxyHex
68053 ± 1.1b G10 68055.4 4 Hex, 4 HexNAc, +IIIb
1 DeoxyHex
aFirst predominant glycoform; bsecond predominant glycoform; cthird predominant glycoform; dmost probable glycan composition within the group
Table 3 Distribution of the major AFP glycoforms in 12 HCC patients. Total AFPs were purified from individual HCC patient serum by affinity chromatography,
and subjected to ESI-MS analysis. The glycan compositions of the identified glycoforms were deduced from their observed masses
HCC case 1 2 3 4 5 6 7 8 9 10 11 12
+Ia +Ia +Ia
AFP +Iba +Iba +Ibb +Ib +Ib +Iba +Iba +Ib +Iba +Iba +Iba +Iba
Glycoforms +Ic +Ica +Ica +Ica +Ic +Ica +Ic +Icb +Ic
+IIa +IIa
+IIb +IIb
+IIcb +IIcb +IIc +IIcb +IIcb +IIc +IIcb +IIcb +IIc
+IId +IIdb +IIdb +IId +IIdb +IId +IId +IIdb
aPredominant AFP glycoform; bsecond predominant AFP glycoformAFP glycoforms were identified in the serum from the NSGCT
patient (Table 2). Their compositions were deduced from the
observed molecular masses after being matched with the hypothet-
ical AFP glycoforms as described above. In total, 10 AFP glyco-
forms were identified from the patient sera. For seven out of the
10 identified AFP glycoforms, there was only one possible glycan
composition that could be deduced from the observed mass for
each of the glycoforms.
Although three out of 10 identified AFP glycoforms (AFPs + Ib,
+ IIb and + IIIa) were matched with more than one hypothetical
AFP glycoforms (Tables 1 and 2), the comparison with those iden-
tified glycoforms with concrete glycan moiety(s) can provide a
clue to decide which one is the most probable glycoform. In the
case of AFP + Ib, its expected theoretical mass is greater than that
of AFP + Ic by 146.1, which is equivalent to the mass of a fucose.
It is possible that AFP + Ib has a glycan moiety similar to AFP +
Ic, but with an additional fucose. Such postulation helps to explain
why only either AFP + Ib (67%, 8 of 12) or AFP + Ic (33%, 4 of
12) appeared as the predominant glycoforms in sera from HCC
patients (Table 3). The presence of AFP + Ib as the predominant
glycoform may be caused by a higher fucosylation activity in
hepatoma cells. Therefore, the fucosylated disialo biantennary
complex-type N-linked glycan (G7) is the most probable glycan
moiety of the AFP + Ib, which is consistent with the identification
of G7 glycans as one of the major glycans released from HCC-
associated AFP (Yoshima et al, 1980; Aoyagi et al, 1993; Johnson
et al, 1999). In the case of AFP + IIb, it was only found in sera with
a negligible amount of AFP + IIc (Table 3). The expected theoret-
ical mass of AFP + IIb is greater than that of AFP + IIc by 203.2,
which is equivalent to the mass of an HexNAc residue (G5). The
absence of the AFP + IIc could be possibly explained by the addi-
tion of a G5 glycan to AFP + IIc, converting it to AFP + IIb.
Therefore the most probable glycan moieties of AFP + IIb are G8
and G5 glycans. For the AFP glycoforms identified in the NSGCT
serum, because G10 glycan is the sole contributor of the carbohy-
drate content of the second predominant glycoform, + IIIb, it is
reasonable to postulate that the AFP + IIIa also carried one G10
glycan, but with an additional G4 glycan (Table 2). Thus, it
appears that glycoforms carrying a G10 glycan predominated in
the NSGCT-derived AFP, and contributed to glycoforms + IIb, 
+ IIIa and + IIIb.
Classification of the identified AFP glycoforms
Since it is known that the isoelectric point (pI value) a glycoprotein
is affected by the number of sialic acid residues (Stibler, 1991), the
identified AFP glycoforms were classified according to their sialic
acid content – Class + I, Class + II and Class + III, carrying two,
one and no sialic acid residues, respectively. In Class + I there were
three subtypes (+ Ia–+Ic); in Class + II there were five subtypes (+
IIa–+IIe); in Class + III there were two subtypes (+ IIIa and + IIIb).
The classification of the identified AFP glycoforms from sera of
the HCC patients and from the NSGCT patient are summarized in
1334 PJ Johnson et al
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Figure 3 Diagrammatic presentation of the glycoforms comprising the AFP
IEF bands +I, +II and +III. The IEF banding pattern of AFP glycoforms is
postulated to be dictated mainly by the degree of sialylation on the glycan
chain(s) of the protein. This is confirmed by the ESI-MS analysis and the
kinetic in vitro desialylation study of the purified AFP isoforms. Class +I, +II
and +II AFPs will be focused as Band +I, +II and +III, respectively
Table 4 The major serum AFP glycoforms, identified by ESI-MS, in AFP preparations that were purified from two HCC patients. Total AFP, Band +I AFP and
Band +II AFP were purified by affinity chromatography and preparative IEF, and subsequently subjected to ESI-MS analysis for 3–5 determinations. The glycan
compositions of the identified glycoforms were deduced from their observed massess
Observed mass by ESI-MS
Identity Deduced glycan
Total AFP Band +I Band +II (calculated mass) composition
AFP AFP
68361a – 68362 AFP +IId G6
(68362.7)
Patient 1 68655 68648 – AFP +Ic G3
(68653.9)
68801 68797 – AFP +Ib G7
(68800.0)
68352 – 68355 AFP +IId G6
(68362.7)
68507 – 68505 AFP +IIc G8
(68506.3)
Patient 2
68651 68655 – AFP +Ic G3
(68653.9)
68797 68802 – AFP +Ib G7
(68800.0)
aappearing as a minor glycoformStructures of alpha-fetoprotein isoforms 1335
British Journal of Cancer (2000) 83(10), 1330–1337 © 2000 Cancer Research Campaign
Tables 1 and 2, respectively. After grouping according to the sialic
acid content, it was apparent that all the identified glycoforms had
similar carbohydrate contents (9–11 neutral monosaccharide
residues). The similarity in the protein core and amount of neutral
monosaccharides in all the identified glycoforms strongly suggest
that differences in the pl values of the glycoforms are dictated
mainly by the number of sialic acid residues.
Distribution and abundance of the identified AFP
glycoforms in different patients
The distribution of the AFP glycoforms in the sera of patients with
HCC is presented in Table 3. The pattern is heterogeneous but
several consistent features emerge. In all cases Class + I AFPs
predominated, whereas Class + II AFPs appeared as the second
predominant glycoforms. AFP glycoforms carrying a single disia-
lylated biantennary complex-type N-glycan (G3 or G7) predomi-
nated in Class + I AFPs, whereas AFP glycoforms carrying a
single monosialylated biantennary complex-type N-glycan (G6 or
G8) predominated in Class + II AFPs. AFP glycoforms carrying
both the N-glycan and O-glycan appeared as minor glycoforms in
the patient sera.
Owing to the rarity of NSGCT patient serum samples with suffi-
ciently high levels of AFP for analysis, we only have been able to
use ESI-MS to elucidate the structure of AFP glycoforms derived
from a single case of NSGCT. No claim, therefore, has been made
for the predominant glycoforms of NSGCT-associated AFP.
However, AFP glycoforms carrying an asialylated biantennnary
complex-type  N-glycan (G10) appeared as the predominant
glycoforms in Class + III AFPs.
Deduction of glycan composition of AFP isoforms
identified by IEF
In all serum samples from the HCC patients, comparison of the
intensities of Band + I and Band + II showed that Band + I
predominated (Figure 2). Similarly, ESI-MS identified Class + I
AFPs as the predominant glycoforms (Table 3). By matching the
abundance, we postulate that Class + I and Class + II AFPs repre-
sent Band + I and Band + II on the IEF gel, respectively (Figure 2
and Table 3). Similarly in the case of NSGCT, Class + II and + III
AFPs should represent Bands + II and + III, respectively (Figure 2
and Table 2).
As the addition of one sialic acid residue decreases the pl value
(of a glycoprotein) by about 0.1 pH (Stibler, 1991), Class + I AFPs
should, if our postulation is correct, have a pl value lower than that
of Class + II AFPs by about 0.1 pH, and the pl value of Class + II
AFPs lower than that of Class + III AFPs, again by about 0.1 pH.
Consistent with this prediction, the pl values of the IEF bands
were: Band + I = pI 4.78, Band + II = pl 4.83 and Band + III = pI
4.90 (Figure 2). The proposed distribution of Class + I, Class + II
and Class + III AFPs on the gel IEF pattern is summarized in
Figure 3. It is apparent that more than one subtype of each class of
AFPs usually coexisted in individual patient serum (Tables 2 and 3).
Furthermore, thick bands were usually seen on the IEF gel (Figure
2). We suggest that, as summarized in Figure 3, several AFP
isoforms, all with very close pl values (those within a class), are
focused at similar positions. Their bands overlap with each other
on the IEF gel, and finally appear as a single thick band.
Identification of glycan compositions of purified Band 
+ I and Band + II AFPs by ESI-MS
To further support our postulated structures for the specific IEF
bands, besides the total AFP we prepared purified Band + I and +
II AFPs from two HCC patients (Figure 2), and subjected them to
ESI-MS analysis. Unfortunately, the level of Band + III AFP in the
NSGCT serum was too low to allow us to purify a sufficient
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Figure 4 ESI mass spectra of the AFP glycoforms in the total AFP (A, D),
Band +I AFP (B, E) and Band +II AFP (C, F) preparations. AFPs were
purified from the sera of two HCC patients (Patient 1: A, B, C; Patient 2: D, E,
F) by affinity chromatography. Band +I and +II AFPs were separated by
preparative IEF before purification
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Figure 5 Conversion of Band +I AFP to Band +II and +III AFPs by sialidase
digestion. Band +I AFP was purified by preparative IEF and affinity
chromatography, and digested with sialidase. The digestion products were
monitored at different time points by IEF-IB. Consistent findings were
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amount for ESI-MS analysis. By ESI-MS (Figure 4 and Table 4),
both Class +I (putatively disialylated) and Class +II (putatively
monosialylated) AFPs were identified in the purified total AFP
preparations (comprising all the AFP glycoforms existing in the
sera). As predicted, Class +I (disialylated) AFPs were, indeed,
predominantly retained in the Band +I AFP preparations, whereas
the Class +II (monosialylated) AFPs were predominantly retained
in the Band +II AFP preparations. However, fucosylated and non-
fucosylated AFP glycoforms were not differentially separated by
preparative IEF. The results of these ESI-MS experiments indicate
that Class +I (disialylated) and Class +II (monosialylated) AFPs
were focused as Band +I and +II AFPs, respectively.
Kinetic in vitro desialylation of purified Band +I AFP
In the presence of sialidase, the purified Band +I AFP, in a step-
wise manner, migrated from the position +I to +II and finally to
+III (Figure 5). Consistent findings were observed on two inde-
pendent occasions. Upon partial sialidase digestion (0.5 h of diges-
tion), microheterogeneity increased immediately, showing a new
alkaline band at position +II. After 2.5 h of digestion, most of
Band +I AFP was converted to the glycoform at position +II. After
5 h of digestion, another glycoform at position +III appeared.
Upon complete digestion (20 h of digestion), the majority of the
AFP protein molecules (asialylated AFP) were still focused as
Band +III. Non-specific effects of incubation conditions were
excluded by control experiments. Conversion of Band +I AFP to
Band +II and +III AFP upon sequential removal of sialic acid
residues confirmed that the appearance of alkaline AFP glyco-
forms (+II and +III) identified by IEF were attributable to a lower
sialic acid content, and asialylated AFP was focused as Band +III.
Thus, this kinetic in vitro desialylation experiment strongly
supports our contention that Band +I, +II and +III are composed of
di-, mono- and a-sialylated AFPs, respectively.
DISCUSSION
Although AFP has been used as a tumour marker for the diagnosis
of HCC for many years, its specificity is poor when levels fall
within the ‘grey area’, i.e. 10–500 ng ml–1 (Johnson et al, 1978;
Okuda, 1986; Lok and Lai, 1989). In this range, differentiation
between benign and malignant liver diseases cannot be made with
confidence on the basis of serum AFP levels alone. There is thus a
need to find a method of increasing the specificity of AFP. Lentil
lectin-reactive AFP has previously been proposed as a diagnostic
marker to discriminate between AFP arising from HCC and AFP
arising from benign liver disease (Du et al, 1991; Taketa et al,
1993; Shimizu et al, 1996). Using the lectin binding properties of
N-glycans with known structures (Yamashita et al, 1993) or
glycosidase digestion (Shimizu et al, 1996) together with lectin
affinity electrophoresis, the carbohydrate structure of the major
HCC-specific AFP glycoform has been suggested indirectly to be
of the fucosylated monosialo biantennary complex-type.
Identification of AFP isoforms is an alternative method to
increase the specificity of AFP. Using IEF and immunoblotting,
AFP isoforms appearing as Band +II and Band +III were found to
be relatively specific for HCC and NSGCT, respectively (Johnson
et al, 1995; Ho et al, 1996; Johnson et al, 1997). The direct struc-
tural analysis of these AFP isoforms in individual patients has,
until recently, been hindered by the extremely small amounts of
serum AFP available. However, with the help of ESI-MS and a
random assembly model (i.e. the construction of hypothetical AFP
glycoforms from the AFP protein core and the known glycans
identified on AFP), we report here an approach that has permitted
simultaneous identification of the predominant AFP glycoforms in
individual patients. The present study provides evidence that the
glycosylation of human serum AFP is more complex than the
single biantennary complex-type N-glycan that has previously
been reported. There exist AFP glycoforms carrying both
O-glycan and N-glycan. The identification of AFP glycoforms
carrying O-glycan was consistent with our previous identification
of O-glycans released from AFP molecules (Johnson et al, 1999).
Our results show that an AFP glycoform carrying a single
monosialo biantennary complex-type N-glycan, either fucosylated
or not, is focused as Band +II. As Band +II AFP is, on the basis
of our previous studies, specific for HCC, our findings suggest
that aside from fucosylated monosialo biantennary complex-
type N-glycan (Yamashita et al, 1993; Shimizu et al, 1996), non-
fucosylated monosialo biantennary complex-type N-glycan is also
the predominant glycan moiety of the HCC-specific AFP glyco-
forms. The AFP glycoform carrying a single difucosylated disialo
biantennary complex-type N-glycan, which had been identified in
a hepatoblastoma cell culture (HepG2) by ESI-MS (Ferranti et al,
1995), was not found in our patient sera. Further investigation is
necessary before we can answer whether hyper-fucosylation of
AFP is a unique property of hepatoblastoma, but not to HCC, or
whether it is due to change in cellular properties upon in vitro cell
culture.
Among the predominant AFP isoforms, in our IEF system, the
one that is commonly identified together with Band +II AFP in
sera of HCC patients and usually occurs alone in sera of patients
with benign liver disease is Band +I AFP (Ho et al, 1996; Johnson
et al, 1997). This ‘benign’ isoform appears to be composed of one
disialylated biantennary complex-type N-glycan. As fucosylation
of the N-linked glycan has been postulated to happen only during
oncogenesis because of loss of cell polarity (Yamashita et al,
1993), the non-fucosylated disialo biantennary complex-type
N-glycan is likely to be the main carbohydrate structure of this
‘benign’ AFP. Unfortunately, the amount of serum AFP in patients
with liver cirrhosis is always too low (< 500 ng mg–1) to permit
purification for the purpose of structural analysis. With the
currently available technology it is therefore difficult to confirm
our suggested structure for the ‘benign’ AFP isoform.
It has been reported that detection of lentil lectin-reactive AFP
by lectin affinity electrophoresis may only discriminate benign
liver diseases from HCC with a maximum diameter of nodules
> 20 mm, but not from early malignancy (maximum diameter of
nodules <10 mm) (Taketa et al, 1993). In contrast, our preliminary
studies have suggested that detection of Band +II AFP may allow
early diagnosis of HCC in high-risk patients even before it can be
detected by routine ultrasound examination (Johnson et al, 1997).
The detection of lentil lectin-reactive AFP may thus be less sensi-
tive than Band +II AFP for early diagnosis of HCC. The appear-
ance of monosialo-AFP (Band +II AFP) in the blood during the
development of HCC in patients with chronic liver disease or
cirrhosis may, in part, be related to a decrease in the sialylation
activity in HCC cells. As a result, the apparent higher specificity of
monosialo-AFP suggests that the decrease in the sialylation
activity may occur earlier than the increase in the fucosylation
activity during oncogenesis in human liver.
In conclusion, three classes of AFPs, +I, +II and +III, are identi-
fied in patient sera by ESI-MS. The predominant AFP glycoformStructures of alpha-fetoprotein isoforms 1337
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in each class carries one disialo, monosialo, or asialo biantennary
complex-type N-glycans, respectively. These three classes corre-
spond to ‘benign AFP’ (appearing as Band +I), ‘HCC-specific
AFP’ (Band +II) and ‘NSGCT-specific AFP’ (Band +III), respec-
tively. Knowledge of the structure of the tumour-specific isoforms
should form the basis for clinically useful assays.
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